629 Neoadjuvant SEMA4D inhibitor pepinemab combination with nivolumab increases crosstalk between B cell and CD26hi T cell in patients with resectable stage III melanoma

• Brian Burns,
• Elizabeth Evans,
• Ragini Kudchadkar,
• Crystal Mallow,
• Christine Reilly,
• Maurice Zauderer,
• Gregory B Lesinski,
• Keith A Delman,
• Chrystal M Paulos,
• Brian Olson,
• Terrence Fisher,
• Jayden Kim,
• Michael C Lowe,
• Ayana T Ruffin,
• Jacklyn Hammons,
• Agnes Harutyunyan,
• Melinda Yushak,
• Ali Mokhtari,
• Douglas Parker

Affiliations

Brian Burns

8 GSA-HEMS Research, Helicopter Emergency Medical Service, SWSLHD, Sydney, New South Wales, Australia

Elizabeth Evans

2 Newcastle University, Newcastle upon Tyne, UK

Ragini Kudchadkar

Aff3 grid.189967.80000000109416502Winship Cancer Institute of Emory University Atlanta GA USA

Crystal Mallow

Aff42 grid.422076.5Vaccinex Rochester NY USA

Christine Reilly

Aff42 grid.422076.5Vaccinex Rochester NY USA

Maurice Zauderer

1Vaccinex, Inc., USA

Gregory B Lesinski

1Emory University, Atlanta, GA, USA

Keith A Delman

Aff3 grid.189967.80000000419367398Emory University Winship Cancer Institute Atlanta GA USA

Chrystal M Paulos

Brian Olson

1Emory University, Atlanta, GA, USA

Terrence Fisher

1Vaccinex, Rochester, NY, USA

Jayden Kim

1Emory University, Atlanta, GA, USA

Michael C Lowe

3Emory University School of Medicine, Atlanta, GA, USA

Ayana T Ruffin

Jacklyn Hammons

1Emory University, Atlanta, GA, USA

Agnes Harutyunyan

2Emory University, Atlanta, GA, USA

Melinda Yushak

5Winship Cancer Institute of Emory University, Atlanta, GA, USA

Ali Mokhtari

2Emory University, Atlanta, GA, USA

Douglas Parker

2Emory University, Atlanta, GA, USA